Mangrove Therapeutics is a preclinical biotechnology company incorporated in November 2025 and registered in Sacramento, California, with research operations described as based in Stanford, California. It is developing first-in-class therapies aimed at a novel RNA-mediated master regulator of inflammation, a target it describes as a gap in polygenic disease biology. The company pairs AI-informed genetic diagnostics with small molecule and siRNA modalities to modulate the causal pathway mediating immune signaling and inflammation, and to stratify patients for treatment. Research is led by Viktoria Kheifets, previously SVP at Alkahest and a biology group leader at Edison Pharmaceuticals; Benjamin Chen is CEO and Alexander Green is CFO and Secretary.